EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

• EDIT-401 showed durable LDL cholesterol reductions of approximately 90% or more in preclinical non-human primate studies, with effects lasting at least six months
• The company plans to file a Clinical Trial Notification in Australia in August 2026 and expects to report top-line results from the phase I/II study in 2027
• Cash position of $211.6 million as of June 30, 2026 is expected to fund operations into the second half of 2028, supported by a $1.3 million restructuring benefit from discontinuing the reni-cel program

Summary: Editas Medicine Q2 2026 Earnings Report

Key Financial Results:

Editas Medicine (EDIT) reported a Q2 2026 loss of $0.15 per share, beating analyst estimates. Collaboration and R&D revenues reached $11.9 million, significantly exceeding the Zacks Consensus Estimate of $2 million and up from $3.6 million in the prior-year quarter. The revenue increase reflects deferred revenues recognized after certain rights expired under the company's Bristol Myers collaboration.

Operational Metrics:

• R&D expenses rose 25% year-over-year to $20.2 million, driven by EDIT-401 preclinical work
• G&A expenses declined 10% to $11.6 million due to workforce reductions
• Restructuring benefit of $1.3 million versus $26.1 million in charges a year earlier
• Cash position strengthened to $211.6 million as of June 30, 2026, up from $123.6 million in March, expected to fund operations into H2 2028

Pipeline Progress - EDIT-401:

The lead candidate is an in vivo gene-editing therapy for heterozygous familial hypercholesterolemia. Preclinical data showed promising results:

• Mean LDL cholesterol reductions of approximately 90% or more in non-human primates
• Durable reductions maintained for six months
• No adverse clinical observations at 1.5 mg/kg dose

Clinical Development Timeline:

• Clinical Trial Notification submission in Australia planned for August 2026
• Phase I/II study initiation expected with four sites across Australia and New Zealand
• Q1 2027 data update anticipated
• Top-line results expected in 2027

Editas currently holds a Zacks Rank #3 (Hold).